drugset / Trial / NCT06308367

The Therapeutic Effect of Betaine in Syringomyelia

NCT06308367

Phase 2 Recruiting 30 enrolled Xuanwu Hospital, Beijing
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Purpose: This clinical trial aims to evaluate the indications, therapeutic effects and side effects of betaine in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before betaine usage.

Timeline

Start
2024-03
Primary completion
2027-03
Completion
2028-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Betaine Small molecule 50 mg/kg Oral

Indications